Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Context and Impact of New Data

Did you know that noncovalent BTK inhibitors are potentially the answer to the development of resistance to covalent BTK inhibitors?

Credit available for this activity expires: 4/5/2023

Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/971263?src=mkm_podcast_addon_971263